The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback